Bafna Pharmaceuticals Ltd.

Total Valuation

Bafna Pharmaceuticals Ltd. carries a market capitalization of 5.02B, placing it among publicly traded companies globally. Its enterprise value stands at 3.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bafna Pharmaceuticals Ltd. currently has 23.66M shares outstanding.

Valuation Ratios

Bafna Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 24.08. The price-to-sales ratio is 1.77, and the price-to-book ratio stands at 11.30.

Enterprise Valuation

On an enterprise value basis, Bafna Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 30.48 and an EV/FCF ratio of 81.26. The EV/Sales ratio of 2.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.48 provides insight into valuation relative to core operating earnings.

Financial Position

Bafna Pharmaceuticals Ltd. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.93, indicating elevated leverage, while an interest coverage ratio of 2.70 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Bafna Pharmaceuticals Ltd. posts a return on equity of 46.92 and a return on invested capital of 9.60.

Taxes

Stock Price Statistics

Bafna Pharmaceuticals Ltd.'s stock has gained approximately 149.04943% over the past 52 weeks. The 50-day moving average sits at 157.98, while the 200-day moving average is 144.52.

Income Statement

Over the trailing twelve months, Bafna Pharmaceuticals Ltd. generated 1.51B in revenue and converted that into 111.00M in net income, yielding earnings per share of 4.69. EBITDA reached 98.75M, while operating income came in at 98.75M.

Balance Sheet

Bafna Pharmaceuticals Ltd. holds 37.37M in cash and equivalents against 374.33M in total debt, resulting in a net debt position of 354.09M. Total book value stands at 236.56M, with working capital of 324.63M providing operational flexibility.

Margins

Bafna Pharmaceuticals Ltd. operates with a gross margin of 31.96, reflecting its pricing power and cost economics. The operating margin of 6.56 and net profit margin of 7.37 provide insight into operational efficiency.

Stock Splits

Bafna Pharmaceuticals Ltd.'s most recent stock split took place on August 26, 2019 with a 10:1 split ratio.

Scores

Bafna Pharmaceuticals Ltd. posts an Altman Z-Score of 3.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.